MEDP

Medpace Holdings Inc

Add to Watchlist

Advanced Chart

298.170

+6.440(+2.210%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

298.650

Open

291.090

VWAP

292.07

Vol

204.33K

Mkt Cap

8.38B

Low

286.030

Amount

59.68M

EV/EBITDA(TTM)

17.45

Total Shares

30.98M

8.47B

EV/OCF(TTM)

14.56

P/S(TTM)

4.57

Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

542.92M

+1.18%

542.78M

+1.77%

537.70M

+1.82%

Estimates Revision

The market is revising Upward the revenue expectations for Medpace Holdings, Inc. (MEDP) for FY2025, with the revenue forecasts being adjusted by 0.93% over the past three months. During the same period, the stock price has changed by -12.50%.

Revenue Estimates for FY2025

Revise Upward

+0.93%

In Past 3 Month

Stock Price

Go Down

-12.50%

In Past 3 Month

7 Analyst Rating

6.82% Upside

Wall Street analysts forecast MEDP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MEDP is 318.50 USD with a low forecast of 285.00 USD and a high forecast of 355.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

6 Hold

0 Sell

Hold

6.82% Upside

Current: 298.170

Low

285.00

Averages

318.50

High

355.00

6.82% Upside

Current: 298.170

Low

285.00

Averages

318.50

High

355.00

Baird

Eric Coldwell

Hold

Maintains

$340 → $313

2025-04-23

Reason

Baird

Eric Coldwell

Price Target

$340 → $313

2025-04-23

Maintains

Hold

Reason

Baird analyst Eric Coldwell lowered the firm's price target on Medpace to $313 from $340 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results and although they are not negative on the shares, they are not overly excited as Bookings remain in "show-me" mode.

Truist Securities

Jailendra Singh

Hold

Maintains

$333 → $300

2025-04-23

Reason

Truist Securities

Jailendra Singh

Price Target

$333 → $300

2025-04-23

Maintains

Hold

Reason

Truist lowered the firm's price target on Medpace to $300 from $333 and keeps a Hold rating on the shares after a post-quarterly call with management to discuss Q1 results, 2025 guidance, bookings trends, future growth prospects, and margins, among other topics. The firm says management is confident in 2025 revenue outlook, but less so on bookings trends.

William Blair

Max Smock

Buy

Hold

Downgrades

n/a

2025-04-22

Reason

William Blair

Max Smock

Price Target

n/a

2025-04-22

Downgrades

Buy

Hold

Reason

William Blair downgraded Medpace to Market Perform from Outperform.

TD Cowen

Charles Rhyee

Strong Buy

Hold

Downgrades

$370 → $328

2025-04-14

Reason

TD Cowen

Charles Rhyee

Price Target

$370 → $328

2025-04-14

Downgrades

Strong Buy

Hold

Reason

TD Cowen downgraded Medpace to Hold from Buy with a price target of $328, down from $370. The firm cites the challenging biotech funding and uncertain regulatory environment for the downgrade. This may lead to slower trial activity and more restricted biotech investment, the analyst tells investors in a research note. TD says that while Medpace will be able to see revenue growth starting in 2026 through market share gains, the macro environment offers little upside in 2025 and an uncertain 2026.

Truist Securities

Jailendra Singh

Hold

Maintains

$347 → $333

2025-04-10

Reason

Truist Securities

Jailendra Singh

Price Target

$347 → $333

2025-04-10

Maintains

Hold

Reason

Truist lowered the firm's price target on Medpace to $333 from $347 and keeps a Hold rating on the shares as part of a broader research note previewing Q1 results for Contract Research Organizations, or CROs. The firm is lowering its estimates and price targets for to reflect recent trends and macro uncertainty. Truist states it had previously believed that large pharma market was already halfway through with respect to portfolio reprioritization, but given the funding trends of the past two months and the uncertain pharma industry environment in general, its baseline assumption now sees biotech recovery being pushed out to at least the second half of 2025 and the large pharma market recovery to the first half of 2026, the analyst tells investors in a research note.

Mizuho

Ann Hynes

Buy

Maintains

$400 → $355

2025-04-09

Reason

Mizuho

Ann Hynes

Price Target

$400 → $355

2025-04-09

Maintains

Buy

Reason

Mizuho analyst Ann Hynes lowered the firm's price target on Medpace to $355 from $400 and keeps an Outperform rating on the shares. The firm surveyed 215 physicians over 13 specialties to gauge hospital inpatient and outpatient trends during Q1. The survey suggests both inpatient and outpatient growth trends, while still elevated, appear to have peaked, the analyst tells investors in a research note. Mizuho views the survey as positive for managed care and clinical labs and neutral for hospitals.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Medpace Holdings Inc (MEDP.O) is 23.95, compared to its 5-year average forward P/E of 29.63. For a more detailed relative valuation and DCF analysis to assess Medpace Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

29.63

Current PE

23.95

Overvalued PE

35.11

Undervalued PE

24.14

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

22.07

Current EV/EBITDA

18.25

Overvalued EV/EBITDA

25.88

Undervalued EV/EBITDA

18.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

4.38

Current PS

4.10

Overvalued PS

5.17

Undervalued PS

3.59